16 results about "Double antibody" patented technology

The application provides a kind of bispecific antibody and its preparation and application, the bispecific antibody includes two chains: from N end to C end in order: VH1 (or VL1), L1, VH2, CH1, the first polypeptide chain of Fc, and from N end to C end in order: VL1 (or VH1), L2, VL2, CL, second polypeptide chain.It is realized tumor selective accumulation by being located in the N end of double antibody structure of the binding domain targeted to tumor associated antigen (TAA), and its shield is located in the inside immune checkpoint antibody fragment to the binding activity of immune checkpoint to reduce systemic activity.

The invention provides a preservation and culture method suitable for in-vitro tissue of a cell line, which comprises the following steps: firstly, cleaning the in-vitro tissue by using PBS (Phosphate Buffer Solution) containing double antibodies, scraping foreign matters on the surface, and then respectively cleaning twice by using 75% alcohol and PBS containing double antibodies to obtain a pretreated sample; then, the pretreated sample is loaded into a sterile sample bag and is vacuumized, and the sterile sample bag is placed in a precooling biological safety transport box, so that long-time and long-distance transport is realized, and cell activity is maintained; and finally, carrying out somatic cell separation and culture on the pretreated sample to obtain primary cells. According to the method, through combination of vacuum treatment and preservation at 4 DEG C, oxidative damage and autolysis of tissues are effectively delayed, and the risks that genetic resources of precious somatic cells are polluted and line establishment fails under difficult conditions such as remote areas are remarkably reduced; through verification, the line can still be successfully established after the tissue is preserved for 14 days, and cells can be stably passaged for 20 generations in vitro in cooperation with an optimized culture medium.

The present application belongs to the technical field of tumor detection and cell separation, and particularly relates to a kit for separating and recovering after immunocapture of circulating tumor cells, a preparation method and application. The kit comprises an immunocapture module, a dissociation and recovery module, a cell protection module and elution and supplement factor solutions. The immunocapture module adopts magnetic microspheres modified by double antibody fusion proteins, can recognize multiple markers such as EpCAM and Vimentin, and realizes efficient capture of heterogeneous CTCs. The dissociation and recovery module uses a low-temperature buffer system and a cleavable cross-linking agent to release cells gently. The cell protection module maintains the integrity and activity of the cell membrane during the separation process. The method of the present application can ensure the capture efficiency while obtaining high-activity CTCs, and is suitable for single-cell sequencing, drug sensitivity analysis, organoid culture and patient-derived cell line construction and other preclinical research.

This invention, entitled "Method, Hybridoma Cells and Their Derivatives, and Applications for Detecting β-1,4-N-acetylgalactosamine transferase (GalNAcT)," belongs to the field of ELISA detection technology. The technical problem to be solved is to improve the limit of detection. The key technical solution is the use of a double-antibody immunosandwich assay, wherein the double antibodies in the double-antibody immunosandwich assay include antibody 1 and / or antibody 2; antibody 1 is secreted by a hybridoma cell line with accession number GDMCC No. 66735, and antibody 2 is secreted by a hybridoma cell line with accession number GDMCC No. 66736.

The invention relates to the technical field of biological detection, and discloses a saliva exosome detection kit for non-invasive auxiliary screening of Alzheimer's disease and a preparation method of the saliva exosome detection kit. The specific exosome enrichment system composed of the anti-L1CAM / CD63 double antibody coated capture plate and the anti-MUC1 / KRT19Fab fragment blocking agent is constructed for the first time, about 85% of oral cavity source exosomes can be effectively removed, and the capture purity of neuron source exosomes is remarkably improved; the special saliva preserving fluid containing DTT and a specific enzyme inhibitor is developed, the technical bottlenecks that saliva RNA is easy to degrade and a sample is uneven in viscosity are overcome, and the room temperature stability is prolonged to 8 hours; an RT-qPCR detection system taking saliva exosome miRNA-135a as a core and taking internal reference miRNA-16-5p standardization is established, and clinical sample verification shows that the kit can effectively distinguish the Alzheimer's disease patient from a healthy control, shows excellent inter-group distinguishing ability, and provides a stable, efficient, reliable and complete technical scheme for solving the problem of AD non-invasive early screening.

The invention provides a double-antibody modified vesicle STING agonist as well as a preparation method and application thereof, and relates to the technical field of polymer nano-drugs. The double-antibody modified vesicle STING agonist comprises a vesicle, an STING agonist and a double-antibody, the vesicle is formed by cross-linking and assembling a functionalized amphiphilic block polymer and an amphiphilic block polymer, an inner cavity of the vesicle is electronegative, the STING agonist is loaded in the inner cavity of the vesicle through electrostatic interaction, and the double-antibody modified vesicle STING agonist is loaded in the inner cavity of the vesicle. The double antibody comprises an anti-HER2 monoclonal antibody and an anti-PD1 monoclonal antibody which are grafted on the surface of the vesicle. The double-antibody modified vesicle STING agonist has good biological safety and can enhance the killing effect of T cells on tumor cells, so that the tumor cells are killed.

The invention discloses a composition for constructing an IOPN organ model, a model construction method and application. The composition for constructing the IOPN organoid model comprises an organoid model culture medium, and the organoid model culture medium comprises a penicillin-streptomycin double antibody solution, GlutaMAX, a serum-free supplement, Rspo-1, a Wnt activator, a growth factor, an HEPES buffer solution, N-acetyl-L-cysteine, a gastrin hormone, nicotinamide, forskolin, an ALK inhibitor, a ROCK inhibitor and the balance of a basic culture medium. The IOPN type organ model cultured by the composition for constructing the IOPN type organ model can maintain the original characteristics of tumors, provides a reliable biological model for pathological research and drug research and development of pancreatic tumors, and is convenient to operate and low in cost.

The present disclosure provides methods for treating cancer in a patient comprising administering a combination therapy comprising a double antibody drug conjugate. In some embodiments, the combination therapy comprises: (i) a therapeutically effective amount of a Trop-2 antibody-drug conjugate (Trop-2 ADC); (ii) a therapeutically effective amount of a Nectin-4 antibody-drug conjugate (Nectin-4 ADC); and optionally, (iii) a therapeutically effective amount of an anti-PD (L)-1 antibody. In some embodiments, the cancer is urothelial cancer.

The application provides a method for genetic reactivation of individual Procyprinus palpebrosus, comprising the following steps: S1, taking the gonadal tissue of Procyprinus palpebrosus, washing, cutting, adding L-15 culture medium containing double antibodies and DPBS buffer solution to centrifuge the gonadal tissue; S2, water-bathing the gonadal tissue to obtain recovered gonadal tissue; S3, digesting the recovered gonadal tissue, filtering, centrifuging and purifying to obtain germ stem cells; S4, injecting morpholino to obtain rare gobi-ocypris rarus with deleted primordial germ cells; S5, transplanting the germ stem cells into the body of the rare gobi-ocypris rarus juvenile to culture, and obtaining the gametes of Procyprinus palpebrosus; and S6, fertilizing the generated gametes of Procyprinus palpebrosus to obtain the individual Procyprinus palpebrosus. The application successfully obtains the sperm of Procyprinus palpebrosus by using the cryopreserved gonadal tissue and the technology of parthenogenesis, and provides a feasible way for the individual genetic reactivation of rare and endangered fish species.

The invention relates to the technical field of biology, in particular to a bifunctional antibody for promoting wound healing reaction and a pharmaceutical composition thereof, at least comprising: a first protein functional region targeting CD4, the first protein functional region being an anti-CD4 antibody or an antigen binding fragment thereof; a second protein functional region, the second protein functional region targeting TGF [beta] 1 / [beta] 2 (especially not targeting TGF [beta] 3), the second protein functional region being an anti-TGF [beta] 1 / [beta] 2 (especially not anti-TGF [beta] 3) antibody or an antigen binding fragment thereof; the double antibody can be safely combined with CD4, but the function of the CD4 is not influenced; by combining with CD4, the double antibody can specifically inhibit a TGF-beta1 signal of CD4 + T cells, so that the inhibition effect of TGF-beta1 on the CD4 + T cells is relieved, and the wound healing reaction mediated by the TGF-beta1 is released; meanwhile, the double antibodies can inhibit TGF-beta2 so as to inhibit the fibrosis promotion capability of the TGF-beta2, and have no inhibition capability on TGF-beta3, so that the wound healing promotion capability of the double antibodies is reserved, and the double antibodies can be used for reducing the scar area after wound healing.

The invention discloses a composition for constructing a complex PNET organ-like model, a model construction method and application. The composition comprises a penicillin-streptomycin double antibody solution, GlutaMax, a serum-free supplement, a Wnt signal channel activator, a human recombinant Noggin protein, a human recombinant FGF10 protein, HEPES, N-acetyl-L-cysteine, gastrin, nicotinamide, an adenylate cyclase activator, an ALK inhibitor, a ROCK inhibitor and a p38MAPK inhibitor. The composition provided by the invention comprises a plurality of growth factors required for vascularization growth of PNET organs, and can meet the requirements of PNET organ cells on nutrient substances and regulation and control substances in a complex structure growth process; in the culture process, a complex PNET organ-like biological model which is closer to the real tumor microenvironment of a human body and is more simulated and more comprehensive is developed, and the PNET organ-like biological model has wider and more important application value in the aspects of clinical diagnosis of PNET diseases, drug research, development and screening, precision medical treatment and the like.

The invention belongs to the technical field of development of molecular nutrition and microcapsule sustained-release particles of aquatic animals, and discloses a method for relieving fatty liver of lateolabrax japonicus and improving muscle quality based on MSTN (myostatin) gene interference, which comprises the following steps: designing a specific fragment according to an MSTN gene coding sequence of lateolabrax japonicus, inserting the specific fragment into an RNA (Ribonucleic Acid) interference vector L4440, constructing a recombinant plasmid, and transforming the recombinant plasmid into HT115 (DE3) escherichia coli; the preparation method comprises the following steps: carrying out multiplication culture in a culture medium containing double antibodies, carrying out IPTG induced expression to generate double-stranded RNA (dsRNA), collecting expressed thalli, and carrying out treatment inactivation with 75% ethanol to prepare microcapsule sustained-release particles. After the microcapsule sustained-release particles are orally delivered, the dsRNA carried by the microcapsule sustained-release particles is subjected to enzyme digestion in the body of lateolabrax japonicus to generate siRNA, and then gene silencing is induced, so that the expression level of the lateolabrax japonicus is remarkably reduced. The interference effect can adjust lipid metabolism distribution between fish body muscles and livers, reduce liver lipid deposition and promote lipid accumulation in the muscles, so that the dual purposes of relieving fatty liver and improving muscle quality are achieved.

The invention provides dual-specific antibodies and methods for manufacturing and using these antibodies. In general, the dual-specific antibodies are generated by identifying a monospecific antibody with electrostatic or hydrophobic light chain variable region (VL) residues and altering the nucleic acid sequence encoding one or more solvent-accessible residues in the antibody's VH, either alone or in combination with altering the nucleic acid sequence encoding the antibody's VL. The altered VH and VL are expressed, and dual-specific antibodies or antigen-binding fragments are selected from them. Examples of dual-specific antibodies and methods for using the antibodies are also provided.

The application discloses a special elution buffer system for significantly removing half-antibody fragment impurities in double-antibody culture and belongs to the technical field of biology. In the elution stage of the eluent in the affinity chromatography capture, the application adds ammonium sulfate to the eluent, removes the half-antibody fragment, improves the purity of the target protein after the affinity chromatography, and makes the purity of the double-antibody meet the demand of a medicine (the SEC-HPLC purity is greater than 97%) after the purification. By using the elution system method, the purity of the half-antibody fragment nr-CE is reduced from 6% to 0.2%.

The invention relates to the technical field of medical monitoring and evaluation, and particularly discloses an SLE curative effect dynamic monitoring and prognosis evaluation system for the rheumatism and immunology department, which comprises a diagnosis phenomenon judgment module, a complement traceability scoring module, a complement traceability evaluation module, a prognosis evaluation module and a prognosis evaluation module, and is characterized in that the diagnosis phenomenon judgment module is used for carrying out bidimensional antibody protein curative effect diagnosis and serum clinical consistency judgment; the method comprises the following steps of: determining an original type of a phenomenon and a current target monitoring object according to a target condition of the phenomenon, and calculating a prognosis initial score, carrying out double-core index regulation and control correlation analysis on a complement C3, and determining periodic stability of an inconsistent event according to change trend analysis of the concentration of the complement C3, and carrying out score multi-maintenance positive module based on the periodic stability analysis of the inconsistent event. Prognosis initial score correction is carried out in combination with time sequence dynamic change and period stability, the system can effectively eliminate false index interference, and the specificity of SLE curative effect monitoring and the accuracy of prognosis evaluation are remarkably improved.

The present invention relates to the technical field of biology, particularly to a bifunctional antibody for treating systemic sclerosis and a pharmaceutical composition thereof, the bifunctional antibody at least comprises: a first protein functional region targeting CD4, the first protein functional region being an anti-CD4 antibody or an antigen binding fragment thereof; the second protein functional region is targeted to TGF [beta] 1 / [beta] 2 / [beta] 3, and the second protein functional region is an anti-TGF [beta] 1 / [beta] 2 / [beta] 3 antibody or an antigen binding fragment of the anti-TGF [beta] 1 / [beta] 2 / [beta] 3 antibody; the double antibody can be safely combined with CD4, but the function of the CD4 is not influenced; through combination with CD4, the double antibody can specifically inhibit a TGF-beta1 signal of CD4 + T cells, so that the inhibition effect of TGF-beta1 on the CD4 + T cells is relieved, and a tissue repair reaction mediated by the TGF-beta1 is released; meanwhile, the double antibodies can inhibit TGF-beta2 and TGF-beta3, so that the fibrosis promoting capability of the double antibodies is inhibited, and the double antibodies can be used for treating systemic sclerosis.